In the evolving field of orthopedic materials, few innovations have garnered as much attention as the i-FACTOR peptide enhanced bone graft. As someone who follows advancements in biotechnology and material science, I have found the development of this specific i-FACTOR bone graft to be a fascinating look at how synthetic biology can influence structural recovery. This article explores the mechanics, clinical context, and technological evolution of this unique Peptide Enhanced Bone Graft.
The Core Technology: P-15 Peptide
At the heart of the product is the P-15 Peptide. To understand its s Cerapedics' i-FACTOR P-15 Peptide Enhanced Bone Graft ignificance, one must look at its biological mimicry. P-15 is a synthetic 15-amino acid sequence that replicates the cell-binding domain of human type-1 collagen. By serving as a powerful cell attachment factor, it creates an environment that encourages cellular interaction.
The i-FACTOR is the first spinal bone graft powered by P-15 Osteogenic Cell Binding Peptide, representing a departure from traditional graft materials. Because i-FACTOR is a composite bone substitute material consisting of this peptide adsorbed onto an organic bone mine Sep 25, 2024 — Cerapedics Wins Expanded FDA Nod for i-FACTOR Bone Graft The company said i-FACTOR can now be used with most commercial interbody cages. ral, it provides a stable scaffold that encourages natural biological processes.
Rigorous Clinical Validation
One of the most impressive aspects of this technology is the clinical data supporting its use. The i-FACTOR met all 4 FDA-mandated noninferiority success criteria, demon Cost-Effectiveness of Peptide Enhanced Bone Graft i-Factor strating both safety and efficacy in long-term fo i-FACTOR Peptide Enhanced Bone Graft llow-up studies. Specifically, researchers have noted that the i-FACTOR reduced costs within the first year by 1.4% to 2.1%, highlighting that this technology is cost-effective compared to autograft in ACDF surgery.
It is important to note that this is a Class III FDA approved bone graft, which signifies the high level of regulatory scrutiny applied to such devices. Because it is a specialized material, it should only be used by doctors who are trained in using it and who understand the specific surgical requirements for its application.
Expansion and Evolution: From i-FACTOR to PearlMatrix
The product landscape has evolved significantly. While the original i-FACTOR Peptide Enhanced Bone Graft remains a staple, the technology has expanded. Notably, i-FACTOR is now approved for single-level anterior cervical discectomy fusion (ACDF), and recent updates have indicated that i-FACTOR can now be used with most commercial in Six-Year Follow-up of a Randomized Controlled Trial of i terbody cages.
Furthermore, th i-FACTOR bone graft is based on synthetic small peptide (P-15) technology developed by Cerapedics to support bone growth through cell attachment and activation. e brand has grown with the introduction of PearlMatrix P-15 Peptide Enhanced Bone Graft. In fact, i-FACTOR®+Matrix is now PearlMatrix P-15 Peptide Enhanced Bone Graft, which is marketed as the first bone growth accelerator proven to accelerate lumbar fusion. This transition reflects the continued refinement of the P-15 technology, with PearlMatrix™ P-15 Peptide Enhanced Bone Graft building upon the same foundational science that made the original product a success.
Key Considerations for Use
The application of this technology is strictly defined. It is indicated for use in skeletally mature patients Expanded Indications for Cerapedics' PearlMatrix P-15 | ORTHOWORLD for specific reconstruction tasks. The i-FACTOR® Peptide Enhanced Bone Graft is designed to be used in conjunction with standard surgical protocols, and its integration into clinical practice is supported by its status as an FDA-designated breakthrough device (specifically regarding P-15L variants).
Whether discussing the original Cerapedics' i-FACTOR P-15 Peptide Enhanced Bone Graft or the newer iterations, the underlying goal remains the same: to provide a consistent, synthetic, and highly engineered environment that supports structural integrity. The shift toward these advanced materials suggests a future where synthetic peptides play a much larger role in how we approach the reconstruction of degenerated tissues, moving away from more invasive, traditional alternatives.
*Disclaimer: This article is for informational purposes only and descr Cerapedics Announces FDA Approval of PearlMatrix™ P ibes technological advancements in orthopedic materials. It does not constitute medical advice, diagnosis, or treatment recommendations.*